ERNAW — Ernexa Therapeutics Inc.

Nasdaq · Health Care · Pharmaceuticals · CIK 748592 ·
Last close
$0.04
Market Cap
52W High
$0.04
52W Low
$0.04
ADV30
9,968
Next earnings
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of treatment of cancer and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-201, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
No quarterly fundamentals indexed for this ticker.

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.02T $1148.84
JNJ JOHNSON & JOHNSON $617.78B $256.35
ABBV AbbVie Inc. $443.36B $250.94
MRK Merck & Co., Inc. $321.57B $130.20
NVSEF NOVARTIS AG $301.30B $158.52

News headlines (Yahoo Finance, 1h cache)

Ernexa Therapeutics CEO Corner Emphasizes How ERNA-101 Could Help Unlock the Next Generation of Combination Cancer Therapies
2026-07-24 13:20 · Yahoo
Ernexa Therapeutics shares soar 30% after independent study validates cancer therapy (ERNA)
2026-07-15 13:43 · Yahoo
Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry
2026-07-15 11:50 · Yahoo
Ernexa Therapeutics CEO Corner Highlights Differentiated ERNA-101 Platform as Company Advances Toward Planned First-in-Human Phase 1 Study in 2026
2026-07-14 13:01 · Yahoo
Ernexa Therapeutics Launches CEO Corner to Provide Deeper Insights into Company Progress, Scientific Strategy and Vision for Patients
2026-06-25 13:15 · Yahoo
Ernexa Therapeutics Positioned to Become a Clinical-Stage Biotechnology Company as ERNA-101 On Track for Planned Q3 2026 IND Submission and First-in-Human Study
2026-06-17 12:47 · Yahoo
Ernexa Therapeutics Highlights Ovarian Cancer Unmet Need, Hope for Patients and Potential Accessibility Advantages of ERNA-101 in Virtual Investor KOL Connect Segment Featuring Dr. Ira Winer
2026-06-09 12:41 · Yahoo
Ernexa Therapeutics Successfully Completes Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development
2026-05-27 12:11 · Yahoo
ERNA Stock Shoots Up 140% in a Month: Here's What You Should Know
2026-05-20 14:45 · Yahoo
Ernexa Therapeutics Releases Virtual Investor KOL Connect Segment Featuring Dr. Elena Ratner Highlighting Ovarian Cancer Landscape and ERNA-101 Opportunity
2026-05-20 12:31 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.